AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 2, 2026 Form 4 reports a director option exercise and separate sale Headline · Source: SEC filing
Nasdaq: $REPLCommercial-stage oncologyU.S. launch underwayConfirmatory survival trial pending

REPL Stock Hub: Replimune Group News, TUDRIQEV Launch and IGNYTE-3

Replimune has launched TUDRIQEV in the United States, but repeat use and cash collections are the next tests of the business. Its $307.8 million of September cash includes the benefit of new equity and debt, while the September quarter ended before commercial availability. The IGNYTE-3 survival trial is a separate test of clinical benefit required under the FDA’s accelerated approval. October 28 financial and business update ยท FDA decision

Last updated: November 21, 2026Financials: fiscal Q2 2027 ended September 30, 2026Currency: U.S. dollars
Full research report ยท PDF
Replimune Group ($REPL), research updated November 21, 2026
19 pages covering launch economics, randomized confirmation, quarterly results, cash use, debt, warrants and ownership. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst
Next expected financial disclosure ยท date not announced

The quarter ending December 31, 2026 is the first that includes U.S. availability. Look for recognized net product sales and the corresponding change in working capital. Company announcements

Completed: the September fiscal quarter was reported October 28; it preceded the commercial launch. Results release
Replimune Group REPL daily stock chart
Daily chart $REPL. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts โ†’

REPL stock at a glance

Chart analysis ยท JC
Technical chart analysis of $REPL with bull and bear scenarios on JC Just Charts.
Cash & equivalents ยท Sep. 30
$307.8M
No short-term investments at quarter-end; restricted cash reported separately.
Net loss ยท fiscal Q2
$57.1M
Quarter ended September 30, 2026; loss of $0.54 per share.
Operating cash use ยท fiscal H1
$123.4M
Hercules term principal ยท Sep. 30
$100.0M
Drawn principal; maturity October 1, 2029.
Common shares ยท Oct. 23
94.8M
94,800,404 shares on the SEC cover; excludes unexercised warrants.
Pre-funded warrants ยท Sep. 30
16.8M
Potential shares; includes the August 2026 warrants.

Where Replimune Group stands now

Replimune announced U.S. availability on October 1. The 10-Q dates the start of ordering to October 2, and the company reported the first patient delivery on October 6. The October 10-Q reported about 20 melanoma institutions had placed it on formulary since availability, with more than 15 institutions having prescribed it and begun treating patients as of October 23. These are measures of initial access, not patient totals or sales figures. The October 28 release also said multiple payer policies had been published covering the approved indication and attributed a category 2A guideline listing to the National Comprehensive Cancer Network. Neither a published payer policy nor formulary access implies that every eligible claim is paid. October 1 launch release ยท Form 10-Q, MD&A and subsequent events ยท October 28 commercial update

The company is commercial, but the reported quarter was pre-launch. The next income statement will be the first opportunity to assess recognized product sales for a period that included availability. Adoption milestones arrive sooner than a randomized survival result.

โ–ฒ Constructive case

Repeat orders and timely collections could lower dependence on outside funding while IGNYTE-3 progresses. Evidence from more than the earliest institutions would make adoption easier to assess.

โ–ผ Cautious case

Access milestones can outrun billable, collected demand, while commercial spending and confirmatory work persist. Lender liquidity tests could matter while the launch is still nascent.

Latest Replimune Group news

Nov 2, 2026

Form 4 reports a director option exercise and separate sale

A director reported an exercise covering 43,169 shares and a separate sale of 21,500 shares on November 2. The Form 4 codes the exercise M and the sale S; the exercise was not an open-market purchase.

Oct 30, 2026

Form 144 proposes a director sale of 10,000 shares

The notice describes shares acquired through option exercise and an approximate sale date of October 30. The form is a proposal, not proof of completion; its separate three-month history reports a 12,000-share sale on October 28.

Oct 28, 2026

Quarterly results report first patient delivery and September cash

First delivery occurred October 6. The company reports more than 15 prescribing institutions, cash of $307.8 million and quarterly net loss of $57.1 million; prescribing and account engagement are not booked product sales.

Oct 1, 2026

TUDRIQEV becomes available in the United States

Availability with nivolumab follows accelerated approval and creates a launch opportunity. Administration, reimbursement and verification of clinical benefit remain distinct obligations.

Aug 19, 2026

Commercial leadership receives inducement awards

The grant includes 150,000 options and 100,000 RSUs, subject to vesting. Compensation awards differ from newly sold common shares or company cash proceeds.

Aug 14, 2026

Quarterly filing documents funding and going-concern conclusion

The filing records the subsequent August offering at about $141 million net and states that conditions raising substantial doubt were alleviated. The proceeds are already reflected in the later September resource balance.

REPL stock catalyst calendar

  • August 6, 2026 โ€” U.S. accelerated approval in the labeled melanoma setting. Completed ยท FDA authorization
  • October 1 and 6, 2026 โ€” Commercial availability and first deliveries to patients, respectively. Completed ยท Company update
  • October 28, 2026 โ€” September fiscal-quarter results and launch update. Reported ยท Exhibit 99.1
  • November 6, 2026 โ€” Quarterly amendment added insider trading plans to Item 5. Filed ยท Form 10-Q/A
  • Date not announced โ€” Results for the fiscal quarter ending December 31, 2026, the first quarter including the commercial launch. Company press releases
  • First calendar quarter of 2027 โ€” Expected preliminary findings in selected RP2 liver and biliary cancer studies. Company expectation ยท Form 10-Q
  • September 2030 / March 2031 โ€” FDA’s IGNYTE-3 study completion and final report milestones. Postmarketing requirement ยท FDA approval letter

Three measures that answer different questions

COMMERCIAL

Access and use

Being listed on a formulary makes use possible within an institution. Prescriptions and patient starts show another step. Revenue and subsequent cash collections measure different steps again.

CLINICAL

Response and survival

IGNYTE response evidence helped support accelerated approval. IGNYTE-3 tests survival against a contemporaneous comparator. Durability in responders is different from survival across assigned groups.

FINANCIAL

Funding and flexibility

The funded balance is a source of time. The ability to deploy it depends on ongoing cash requirements, lender terms, and the relative costs of the commercial and trial programs.

How to read the first commercial quarter

The first set of launch accounts should be read in sequence. Start with net product revenue, then look at receivables and cash from operations. A shift in receivables can have several explanations: more shipments, a change in customer mix, normal billing lags or collection friction. It is the relationship across periods that makes the distinction possible. An increase in net sales accompanied by a materially larger increase in receivables would call for a different interpretation than the same sales increase accompanied by prompt collections. The September baseline has inventory but no post-launch product revenue, so the two periods cannot be compared as if they were equivalent sales quarters. Form 10-Q, balance sheets and subsequent events

Then ask how much of the change is due to launch timing. Distribution activity that fills the channel can occur on a different schedule from demand at treating sites. A few strongly performing centers can drive the first set of results without resolving how far adoption extends. It would be helpful to see whether net sales expand alongside repeat activity from a larger set of institutions, or whether the next positive numbers are still confined to initial access decisions. This separates the geographic and institutional breadth of demand from the absolute dollars collected.

Finally, compare the commercial result with the resources it consumed. An improvement in sales is more valuable if it needs progressively less incremental spending per dollar of revenue. The pre-launch line for selling, general and administrative expense supplies a starting point, not a target for the post-launch organization. A higher expense base may be justified during access expansion; without a matching trend in use, the rise would make the cash runway more sensitive to decisions elsewhere in the portfolio. The balance sheet and cash-flow statement will be more useful together than either headline alone. Form 10-Q, statements of operations and cash flows

Replimune Group deep dive: the full analysis

The chapters connect the evidence supporting the U.S. launch to the randomized survival requirement and the financial resources available to the company. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios for Replimune after launch

Bull case โ€” initial reach becomes repeat demand

The favorable case starts with repeat orders from the institutions that moved early, followed by orders from centers that took longer to make a formulary and reimbursement decision. A prescription from a leading melanoma center tells the reader that at least one institution can navigate the access process. A second and third prescription from that center, followed by activity at other centers, would tell a different story: the change in clinical practice might outlast the initial interest in the approval. The first financial evidence would be a product revenue line that can be reconciled with receivables, inventory and ongoing commercial expenses. It is possible for all four to rise at first; what matters is whether collections begin to support revenue rather than merely follow it at an increasing distance.

The stronger version of this case also requires progress in IGNYTE-3. An enrollment update with a denominator, meaningful breadth across sites and clarity about the schedule would help distinguish study execution from a general statement that a trial is on track. If recruitment progresses while early revenue begins to absorb some of the launch expense, the financial and clinical timelines become easier to bridge at the same time. These are separate tests. Good sales would not answer the survival question, and good recruitment would not pay the interest bill. The combination would be valuable because neither program would have to carry all the risk of the other.

Base case โ€” adoption is real but uneven

In a middle scenario, major centers are first to incorporate the therapy, while secondary centers take longer to develop referral arrangements and obtain predictable reimbursement. Early shipments can produce a revenue line before there is much evidence of demand outside the first group of centers. From one quarter to the next the mix of first orders and repeat orders could change materially. It may take more than one report to judge whether caution at later sites reflects normal adoption friction, local practice preferences or a hard limit on the commercially reachable population.

On that path, the August equity raise and September debt draw provide a bridge. It supports a trial with years of follow-up alongside a commercial effort that must show economics much sooner. Management would still have choices about how aggressively to fund the rest of the pipeline and whether to preserve cash or draw additional debt. Neither an initial revenue line nor a decline in research spending would justify using a mature commercial margin in a model. Evidence of utilization, expense discipline and cash conversion would matter more than extrapolating a single period of growth from a near-zero starting point.

Bear case โ€” accessible patients are fewer than the label suggests

A broader indication can coexist with a much narrower practical market. Some patients may need a treatment that fits their disease distribution or current clinical course better; others may not be able to travel to a center equipped to offer this therapy. If early institutions order for select patients but do not use the product regularly, formulary counts could rise without a commensurate increase in treatment or revenue. Cost will still be incurred to support the launch and the confirmatory obligation. A release showing more sites but little revenue would be more concerning if the same pattern persisted after those sites had time to establish access.

The most difficult outcome would be a commercial shortfall accompanied by a slower or more expensive confirmatory program. That could make the equity market relevant again sooner than the balance sheet suggests. Existing lenders and holders of securities with nearly all their exercise consideration already paid would have different economics from an ordinary share purchased today. The downside is therefore not just a slower revenue curve; it is the possibility that further financing becomes necessary before new evidence can improve the terms available to the company.

What would falsify this reading

  • Rapid conversion of orders into recurring collections. If regular reorders spread outside the first group of institutions and cash collections start offsetting operating expenses, the view that this remains primarily a financed launch would need revision. Sustained results across more than one reporting period would carry more weight than a large initial shipment.
  • Persistent lack of conversion despite broad access. If company-reported formulary access expands but patient starts, net sales or collections lag for several periods, a temporary reimbursement explanation becomes less persuasive. The case for a durable commercial franchise would weaken even with the approved indication unchanged.
  • A change in the clinical obligation. A material change in the approved indication, a revision of the confirmatory commitment or randomized survival evidence would change the clinical premise. An updated response statistic from the original single-arm study would refine one part of the evidence without replacing that test.
  • Capital constraints before the operating case is measurable. A material decline in available cash, covenant pressure or a large financing before meaningful launch evidence would change the value of the September cushion. A high cash balance and a shrinking pool of freely deployable capital can coexist.

02 What Replimune Group does

Replimune is an oncology biotechnology company with one U.S. commercial product and an investigational portfolio. TUDRIQEV is the commercial name of RP1, now known as vusolimogene oderparepvec-wtpg. Its FDA indication is in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. That wording defines a treatment setting, not all melanoma and not a general indication for other solid tumors. The company describes it as an oncolytic immunotherapy: for the investment case, the question is whether the observed antitumor responses translate into durable clinical benefit and use in the approved population. FDA approval notice

The business is now doing several kinds of work at once. It supports an approved product, funds the confirmatory trial, and retains exposure to earlier pipeline programs. Those activities produce different outputs. A formulary decision helps a hospital make a product available; a trial participant helps answer a scientific question; cash collected from a customer helps fund the organization. Treating all of these as simple progress understates the possibility that one area can advance while another falls behind. The October earnings release offered the first perspective on that separation because it included a post-period commercial update alongside a pre-launch income statement. October 28 results and corporate update

Replimune has also described clinical collaborations, including Bristol Myers Squibb (BMS) supplying nivolumab at no cost for specified studies under a clinical trial collaboration and supply agreement. That support relates to those studies; it does not mean that Replimune records nivolumab revenue under the U.S. melanoma label. The October filing also describes a Roche collaboration in hepatocellular carcinoma. Such relationships can help a company test its candidate with existing therapies, but they do not make every cohort an economic partnership with milestones or royalties. For modeling the business, trial supply, development cooperation and a commercial profit share would each require their own contractual basis. Form 10-Q, MD&A: Collaborations

Management’s immediate choice is how to distribute attention across the business. An organization designed to prepare a filing can manage to a relatively crisp deadline. A commercial organization must support a stream of customers whose adoption decisions have no single common date. A confirmatory program has its own timetable, with the most informative result dependent on follow-up as well as recruitment. Early-stage programs can generate independent options, but only if enough resources remain available to make a fair test. Those activities compete for staff and cash even when they advance the same long-term strategy.

03 REPL stock catalysts: commercial reporting and the confirmatory clock

There are two clocks after the October launch. The first is financial: the first fiscal period with commercial availability is the quarter ending December 31, 2026. Its results can show whether sales were recognized, but the first delivery did not give the amount or timing of recognition on its own. No date for that earnings release had been announced by November 21. A quarterly filing will be a stronger basis for judging adoption than a launch anecdote because it can connect net product revenue with the balance sheet and cash-flow statement. Form 10-Q, subsequent events and fiscal year ยท Replimune press release calendar

The second clock is clinical. The FDA’s approval letter specifies September 2030 for IGNYTE-3 study completion and March 2031 for submission of the final report. ClinicalTrials.gov lists estimated primary completion on September 30, 2030 and estimated study completion on March 31, 2031. These entries describe different milestones in different records. Neither says when a press release with survival data will appear, and neither supplies a date for conversion to traditional approval. A confirmatory result can be discussed publicly before or after a regulatory submission, depending on the facts and the company’s disclosures at that time. FDA approval letter, postmarketing requirement ยท IGNYTE-3 registry

A third development track is the company’s expectation of preliminary RP2 findings in advanced liver and biliary tract cancers in the first calendar quarter of 2027. The October filing describes the program and the expected window, not a conference presentation or final data date. Preliminary evidence in one cohort would not automatically validate the same approach in the other cohort. It also would not directly answer the uveal melanoma question that REVEAL was designed to address. These lower-certainty readouts matter mainly for whether management continues allocating research spending to an additional cancer program while it funds the melanoma launch. Form 10-Q, MD&A: RP2

It is tempting to count these events equally in a catalyst calendar. They have different consequences. The next reporting period can alter the runway interpretation and the commercial opportunity; the final confirmatory results can affect the regulatory status of the existing product; exploratory RP2 data may inform future investment without changing the existing label. The stock can react to any one of these, but the economics mostly depend on whether the financial clock supplies enough time for the clinical clock to run.

04 The FDA decision: what accelerated approval changed

Approval in August 2026 came after a first complete response letter in July 2025 and a second in April 2026. A complete response letter says that the application could not be approved in its existing form at the time; it is not a permanent prohibition on a new regulatory submission. The FDA’s August letter acknowledges a June 2, 2026 amendment that constituted a complete response to the April action letter. The advisory committee discussed the application on July 30; the FDA issued the approval on August 6. The panel voted 10โ€“3 that the IGNYTE efficacy evidence was evaluable and clinically meaningful; it did not issue the approval. The FDA review describes disputes over response assessment and whether the combinationโ€™s effect could be separated from that of its components. The August decision considered the additional analyses and advisory input while leaving confirmation of clinical benefit to the randomized trial. FDA regulatory review FDA approval letter ยท FDA oncology approval notice ยท Form 10-Q, Legal Proceedings

The agency based accelerated approval on objective response rate and duration of response. The authorization made U.S. commercialization possible for the labeled combination, but continued approval may depend on verifying clinical benefit. In this setting a response is a measurable change in the tumor assessment under defined criteria. A durable response adds time to that observation. A survival comparison asks what happened to the randomized patients as a group against a treatment alternative. One measure can give the FDA a reason to allow access before the other matures; the latter can still materially change what is known about the treatment’s benefit. FDA rationale for accelerated approval

The words โ€œin combination with nivolumabโ€ carry commercial as well as clinical significance. Readers should not convert TUDRIQEV sales into total spending on the regimen. The company may benefit from being able to offer a new option after prior PD-1 therapy, yet decisions on the sequence of treatments remain affected by prior regimens, disease characteristics and the setting in which the product is offered. A single indication also leaves the company exposed to a concentrated label and the fortunes of one program rather than different products in different markets. U.S. prescribing information, indications and usage

Label safety limitations affect the market reachable by an approved drug. The prescribing information lists contraindications, including for immunocompromised and pregnant patients, and describes precautions and adverse reactions. The clinical interpretation of those warnings belongs with the full label and the treating team. From a business perspective the relevant question is how many centers can support use in the patients who are eligible and whether that changes the referral pattern. The risk profile is also relevant to what happens after launch: uncommon adverse events, new evidence or operational friction could affect use without a change to the indication itself. U.S. prescribing information, contraindications and warnings

FDA approval should not be exported by analogy to another regulator, another tumor type or an earlier stage of disease. The approval letter concerns a U.S. license for a specific melanoma indication. International economics would depend on a separate pathway, and an early-stage program would need its own clinical evidence and regulatory outcome. The incremental hurdle is particularly important when discussing an indication where patients may live longer and clinical endpoints, comparator choices and risk tolerance can differ.

05 IGNYTE: the response evidence in context

Wong et al. reported the single-arm IGNYTE melanoma cohort in the Journal of Clinical Oncology in 2025. The study included 140 patients with advanced melanoma after confirmed progression on anti-PD-1 therapy. Independent central review reported a 33.6% objective response rate using modified RECIST, the published primary endpoint. Using RECIST 1.1 instead, the confirmed objective response rate was 32.9% (95% confidence interval, 25.2% to 41.3%) and the complete response rate was 15.0%. The published median duration of response was 33.7 months, with a March 8, 2024 analysis cutoff. About two-thirds had primary anti-PD-1 resistance and 46.4% had previously received both anti-PD-1 and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) therapy, either in combination or in sequence. These were observed outcomes in the study population, not a comparison against another treatment. Wong et al., Journal of Clinical Oncology, 2025

For the label, the FDA reported a 24.2% objective response rate (95% confidence interval, 15.8% to 34.3%) and a median duration of response of 14.1 months in its efficacy-evaluable set of 91 patients with at least one noninjected lesion. The FDA and journal estimates use different analysis populations from the same study; subtracting the percentages would not measure a decline in effectiveness. The distinction is especially relevant to estimates of duration, because the median can move as formerly ongoing responses mature. Neither the longest response nor the median duration for responders tells a reader how long the typical enrolled patient lived. FDA efficacy summary ยท Wong et al., IGNYTE results and data analysis

The paper also reported treatment-related grade 3 events in 9.3% and grade 4 events in 3.6%, with no grade 5 treatment-related events in that cohort. This describes the observed sample rather than the absence of a rare risk in clinical practice. Comparisons of safety across studies require attention to attribution and denominators: treatment-related events differ from all treatment-emergent events, and events in patients who started a treatment differ from events across all patients assigned to it. Reported tolerability can also be affected by how long participants are followed and how long they stay on treatment. Wong et al., clinical safety results ยท FDA prescribing information

Why does a single-arm result matter at all? Responses after progression in a difficult setting can justify a closer look, particularly when some last well beyond the first assessments. But patients enrolled in a study are selected: prior therapy, performance status and disease characteristics all shape the observed result. A historical series can help frame the clinical problem; it cannot replace a concurrent control drawn under the same eligibility rules. If the patients entering a trial had better access to subsequent care, for example, that could affect observed survival without changing how much benefit the study drug itself conferred.

The earlier experience with talimogene laherparepvec reinforces this point without settling the Replimune question. In OPTiM, Andtbacka et al. reported an independently assessed durable response rate of 16.3% versus 2.1% with the comparator in the primary analysis. That is a historical randomized comparison in a different melanoma population. In the phase 3 MASTERKEY-265 study, Chesney et al. found that adding talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival versus placebo plus pembrolizumab in previously anti-PD-1-naive advanced melanoma. The settings, drugs and endpoints differ from IGNYTE-3. Together the studies illustrate why response and survival need to be interpreted independently and why early combination activity can be clinically interesting without predicting a later randomized result. Andtbacka et al., Journal of Clinical Oncology, 2015 ยท Chesney et al., Journal of Clinical Oncology, online 2022

06 IGNYTE-3 and the post-PD-1 treatment landscape

IGNYTE-3 is a randomized, open-label phase 3 study of TUDRIQEV plus nivolumab versus physician’s choice. The FDA postmarketing requirement calls for about 400 patients randomized equally between the two arms, with overall survival as the primary endpoint. It describes enrollment in patients with confirmed progression after anti-PD-1 and anti-CTLA-4 therapy in combination or in sequence. That treatment history is narrower than the wording of the approved adult indication. The trial registry also lists progression-free survival and objective response rate as secondary outcomes. A headline about response in this trial would be useful, but those are not interchangeable endpoints. FDA postmarketing requirement ยท ClinicalTrials.gov, study design and outcome measures

Randomization is the central change because it helps balance factors that could otherwise make a comparison misleading. An open-label design means treatment assignment is known, which may affect some management choices and assessments. Overall survival is a direct outcome, but its interpretation still benefits from knowing the follow-up and the therapies received after progression. When results become available, the point estimate, confidence interval, number of events and consistency across prespecified groups will be more informative together than a shorthand description of a positive or negative trial.

Existing treatments already shape the comparator environment. In SWOG S1616, Vanderwalde et al. randomized 92 eligible patients with advanced melanoma refractory to PD-1 or programmed death ligand 1 (PD-L1) blockade. Ipilimumab plus nivolumab improved progression-free survival versus ipilimumab alone, with a hazard ratio of 0.63 and a 90% confidence interval of 0.41 to 0.97. Grade 3 or higher treatment-related adverse events occurred in 57% versus 35%. That trial gives evidence for checkpoint combination treatment in its own setting. It does not say how the two IGNYTE-3 arms will perform after patients have already received both classes. Vanderwalde et al., Nature Medicine, 2023

Lifileucel offers another route for some patients after prior treatment. Chesney et al.’s pooled phase 2 analysis in the Journal for ImmunoTherapy of Cancer reported a centrally assessed response rate of 31.4% in 153 treated patients, with a median of three prior lines. The FDA granted accelerated approval in February 2024 for adults with unresectable or metastatic melanoma after prior treatment with a PD-1 blocking antibody, and after BRAF-targeted therapy where applicable under the label. The FDA efficacy analysis and the pooled publication use different analysis populations. Similar response rates across the two trials leave differences in benefit, access and safety unresolved. The products also ask different things of patients and centers, so a comparison limited to the response figures tells little about how physicians will choose among eligible options. Chesney et al., Journal for ImmunoTherapy of Cancer, 2022 ยท FDA lifileucel approval notice

Initial treatment shapes the later-line pool. The ten-year CheckMate 067 results from Wolchok et al. illustrate that some previously untreated patients receiving checkpoint therapy have very long survival. That is evidence about the first-line setting, not an expectation for patients who have progressed despite one or more checkpoint regimens. The distinction matters commercially: incidence of melanoma, incidence of advanced melanoma, progression after a PD-1 regimen and eligibility for a particular later-line treatment are different denominators. Even within that last group, the treating team has to judge disease tempo, prior adverse events and feasible referral options. Wolchok et al., New England Journal of Medicine, online 2024

The confirmatory comparison will therefore be clinically important even if there is significant early uptake. Use in ordinary practice does not assign patients to comparable arms; it reflects choices made by physicians, patients and institutions. Positive clinical anecdotes might explain adoption. They would not resolve whether patients live longer than a comparable group receiving physicians’ choice of therapy. Conversely, an improvement in overall survival would not itself resolve whether real-world access is broad enough for the commercial case. These are complementary questions and need different answers.

07 Beyond the launch: RP2 and other indications

Replimune’s October release described REVEAL, a registration-directed phase 2/3 trial in metastatic uveal melanoma, as actively enrolling. It compares RP2 plus nivolumab against ipilimumab plus nivolumab, with overall survival and progression-free survival as primary endpoints. The design places a survival-related comparison inside the trial rather than relying on the magnitude of a response in a small early cohort. โ€œRegistration-directedโ€ describes the program’s aim; a successful clinical and regulatory outcome is still needed before sales could follow. October 28 release, RP2 program update

Uveal and cutaneous melanoma share a name, but the evidence from one cannot supply the clinical benefit in the other. The benchmark of tebentafusp in metastatic uveal melanoma illustrates how much a specific population can matter: Nathan et al. demonstrated an overall survival advantage in a phase 3 trial in previously untreated patients with a particular human leukocyte antigen (HLA) type. That population and clinical line differ from many of the practical options faced by patients after prior therapy. It is a precedent for survival evidence, not a read-through to RP2’s magnitude of benefit or commercial reach. Nathan et al., New England Journal of Medicine, 2021

The October 10-Q also describes separate RP2 programs in hepatocellular carcinoma and biliary tract cancer. They should be read as different clinical hypotheses rather than a single pooled liver cancer opportunity. Prior treatments, available options and the outcome measures that matter can differ by disease. Before any preliminary report is assigned financial significance, it will matter how many patients contribute, how mature the follow-up is and whether activity can be distinguished from the effect of the companion therapy. A short readout can justify more investment without proving the economic value of an indication. Form 10-Q, MD&A: investigational portfolio

The company also carried costs for RP1 programs outside marketed melanoma, including ARTACUS and CERPASS, in the September 10-Q. In cutaneous squamous cell carcinoma, established PD-1 options are relevant context: Verkerk et al. described prospective real-world outcomes with cemiplimab, including a 35.1% objective response rate in a 151-patient cohort. That population is not a substitute for a dedicated study in patients with a transplant, differing immunosuppression or prior treatment, nor does it provide an efficacy benchmark for an RP1 cohort with different criteria. The opportunity is best evaluated program by program rather than by moving an outcome from one skin cancer or clinical setting to another. Form 10-Q, research and development expenses by program ยท Verkerk et al., The Lancet Regional Health โ€“ Europe, 2024

There is a financial trade-off in maintaining these options while the lead franchise is in its first commercial year. Preserving a second indication can reduce long-term dependence on TUDRIQEV, but each serious development program uses cash that could otherwise lengthen the runway for the confirmatory trial and the launch. Conversely, pruning development can conserve cash while leaving the company more exposed to one label. The program-specific research table is useful because it shows that allocation changing before a portfolio reorganization is necessarily visible in headline spending.

08 Fiscal second-quarter 2027 earnings: the last pre-launch comparison

Replimune’s fiscal year ends March 31, so the three months through September 30, 2026 were the second quarter of fiscal 2027. The October 28 release included developments after the quarter closed, but the launch did not contribute product revenue to the September income statement. The figures below are in millions of U.S. dollars except per-share amounts; expenses are shown as positive outlays and losses as negative results. Form 10-Q, statements of operations and MD&A ยท October 28 earnings release

Line itemThree months to Sep. 30, 2026Three months to Sep. 30, 2025Six months to Sep. 30, 2026
Product revenueNoneNoneNone
Research and development34.36557.87783.644
Selling, general and administrative21.91626.41440.885
Operating lossโˆ’56.281โˆ’84.291โˆ’124.529
Other income (expense), netโˆ’0.8401.191โˆ’2.358
Net lossโˆ’57.121โˆ’83.100โˆ’126.887
Basic and diluted net loss per shareโˆ’$0.54โˆ’$0.90โˆ’$1.26

The quarter’s $34.365 million of research and development plus $21.916 million of selling, general and administrative expense equals the $56.281 million operating loss. Below operations, $0.238 million of research incentives, $1.880 million of investment income and $0.067 million of other income were more than offset by $0.502 million of interest on finance leases and $2.523 million of interest on debt. That bridge accounts for the $0.840 million net other expense and the $57.121 million net loss. The prior-year quarter had net other income instead, so the improvement in net loss was smaller than the improvement from operations. Form 10-Q, condensed consolidated statements of operations

The lower expense total hid a redistribution within research. Direct RP2 spending was $9.439 million versus $5.253 million a year earlier, while IGNYTE-3 was $6.818 million versus $6.474 million. Unallocated research expense declined to $16.039 million from $34.420 million. The confirmatory study thus remained a meaningful cost even as total spending came down, and RP2 absorbed more dollars than the lead product’s confirmatory study when measured by the reported direct allocations. The reported allocations alone do not say how much an individual program costs once shared staff and other indirect expenses are included. The relevant comparison is the progression of the same line items across periods, not competing fully loaded program budgets. Form 10-Q, MD&A: expenses by program

Cost comparisons also span a restructuring. The fiscal 2026 annual report says Replimune began a reduction of about 55% of its workforce in April 2026 after the second FDA response letter. The September 10-Q says the restructuring affected the entire commercial team and that rehiring began to ramp up later in the quarter after approval. That sequence helps explain why the pre-launch drop in overhead is a poor estimate of what a commercial organization will cost. Fiscal 2026 Form 10-K, Human Capital and Subsequent Events ยท September MD&A, selling and administrative expenses

The fiscal third quarter will introduce cost and revenue categories that cannot be read off the September financial statements. A sales number without its collection cycle says little about cash use. An improvement in operating loss after launch could depend on the timing of recognized revenue, inventory costs and sales deductions, not solely on higher patient use. If commercialization increases selling expenses before net sales are large enough to defray them, a larger revenue figure can coexist with wider cash use. This is why the September quarter is a useful expense baseline, even though it cannot measure the economics of an active launch.

09 Cash, restricted balances and the runway bridge

At September 30, 2026 the balance sheet showed $307.833 million of cash and equivalents, no short-term investments, and $1.703 million of restricted cash reported separately outside current assets. At March 31 those categories were $209.024 million, $59.865 million and $1.703 million, respectively. The two unrestricted balance-sheet categories together rose by $38.944 million from March to September. The $98.809 million increase in cash and equivalents alone is larger because it also reflects the move out of short-term investments. Restricted cash is excluded from both comparisons of deployable resources. Form 10-Q, balance sheets and statements of cash flows

For the six months ended September 30, operations used $123.430 million. Net investing cash inflow was $59.756 million, chiefly from securities maturities and sales net of purchases, with $0.083 million of purchases of property, equipment and software capitalization and $0.080 million from sales of property and equipment. Financing supplied $161.349 million net, and exchange rates added $1.134 million. Together these reconcile to the $98.809 million change in cash and equivalents because restricted cash was unchanged. Sales and maturities of investments convert one financial asset into another; they are not sales of TUDRIQEV or recurring cash generated by the business. Form 10-Q, six-month cash-flow statement

The cumulative operating figure also obscures a meaningful sequential difference. The June-quarter 10-Q reported $75.728 million of operating cash use. Subtracting it from the six-month figure yields $47.702 million for the September quarter, a Merlintrader calculation, against $81.212 million for the prior-year September quarter on the same basis. Adding the first-half $0.083 million of gross capital spending to operating use gives $123.513 million of first-half operating and gross capital cash use, before any financing or proceeds from asset sales. That is an analytical measure, not a company-defined adjusted loss or a forecast. September Form 10-Q, cash-flow statement ยท June Form 10-Q, cash-flow statement

The first-half monthly average of operating cash use was about $20.6 million. At that static rate, September cash and equivalents divided by the average would give about 15 months of simple coverage. Using the more recent quarter alone would give about 19 months. Neither calculation forecasts future sales, shifts in working capital or required liquidity under the secured loan, and they should not be read as a forecast of when cash runs out. Both are useful because they show how materially the denominator changes the interpretation. In a launch the rate can move in either direction as inventory moves, patient billing matures and the cost of selling the product changes. September 30 cash and first-half cash flows ยท June quarter operating cash flow

Management said the August equity financing alleviated the substantial doubt that existed at the time of the March 31, 2026 annual financial statements. At the issuance of the September interim statements, it expected the available cash resources to fund operations and capital expenditure requirements for more than twelve months, including commercialization and operating needs. Accounting for substantial doubt is anchored to a specified period and available resources. The FDA’s confirmatory reporting deadline lies well beyond that assessment period. A lender cash test or the need to raise capital on acceptable terms can matter well before a purely arithmetic cash balance would reach zero. Form 10-Q, Note 1 and Liquidity and Capital Resources ยท Company cash outlook, October 28

10 Hercules debt: principal, maturity and the cash covenant

Replimune drew $15.0 million under the fourth amendment to its Hercules Capital facility on September 29, 2026. The September 30 principal was $100.0 million; its balance-sheet carrying amount net of discount was $99.766 million, with $24.376 million of finance lease liabilities reported separately. Cash less face principal was $207.833 million before lease liabilities and other obligations, a Merlintrader calculation, not the contract’s unrestricted-cash measure. A debt-to-earnings ratio would not be informative against a pre-launch operating loss; the contractual tests are more relevant for near-term flexibility. Form 10-Q, balance sheet and Note 8: Debt

The FDA approval triggered the extension of the term facility’s maturity to October 1, 2029 under the agreement. The company describes interest-only payments through September 2029 and a floating cash interest rate equal to the greater of 8.50% and the prime rate plus 1.75%. It also accrues 1.50% payment-in-kind interest, added to principal on each interest payment date. The fourth amendment also made another advance of up to $15 million available subject to its deadline and conditions; the March 31, 2027 window and related conditions apply to that additional advance, which is not included in the principal actually drawn at September 30. A loan extension changes the schedule of principal repayment, but it does not remove interest, contractual fees, security or conditions for access. Form 10-Q, Note 8: amendment, interest and maturity

The performance covenant takes effect at the later of July 1, 2026 and outstanding term principal reaching $100 million. The 10-Q describes three alternative ways to satisfy that covenant. One uses a minimum trailing three-month net product revenue test measured monthly. A second combines a contractual capitalization threshold of more than $1.2 billion and unrestricted cash of at least 50% of outstanding term loans. A third uses unrestricted cash of at least 85% of term loans. At $100 million of principal, the two percentage amounts imply $50 million and $85 million respectively; the first figure only applies alongside the capitalization condition. A subsequent increase in principal would increase each dollar amount if the percentages were unchanged. The September cash line is not a live covenant certificate, and the contractual threshold is not an estimate of REPL’s current market value. Separately, the fourth amendment sets a continuous unrestricted cash floor at 35% of aggregate secured obligations plus the contract-defined accounts-payable amount. That percentage falls to 20% when both the approval milestone has been achieved and the performance covenant is effective. The contract specifies what counts toward secured obligations, including applicable charges. Form 10-Q, Note 8: Hercules financial covenants ยท Fourth amendment, ยง2.2

Those paths create a different set of operating trade-offs than a simple maturity date. When revenue is new, the cash alternatives can provide flexibility, but only while eligible cash remains sufficient. Reporting unrestricted cash in a covenant also gives an investor a reason to distinguish readily available money from account balances that may be unavailable under the agreement. Drawing an optional advance would increase the cash inflow while also increasing interest, principal and potentially the absolute cash needed under the percentage tests. The financing decision is more complex than choosing between debt that adds no shares and equity that does.

11 REPL share dilution: common stock, warrants and available capacity

Basic common shares rose from 82,716,923 at March 31 to 83,979,366 at June 30 and 94,805,154 at September 30, 2026. The October 23 cover-date count was 94,800,404. That later printed number is slightly lower than the quarter-end total; the two represent different dates and do not prove a repurchase. The quarter bridge is exact: the June count plus 9,701,490 offering shares, 652,820 option exercise shares and 471,478 shares from vested restricted stock units equals the September total. The August warrant proceeds increase capital without adding those warrant shares to the legal count at closing. Form 10-Q, cover and statements of stockholders’ equity

The August financing sold common stock at $12.06 per share and pre-funded warrants covering 2,736,340 shares at $12.0599 each. It produced $150 million gross and approximately $141 million net after fees and expenses. The offering funded the business immediately; the nominal exercise payment is separate and would add little cash. The quarter-end warrant total of 16,794,493 already includes the August issue. Combining the legal common count with all pre-funded warrant shares gives 111,599,647 common equivalents on a simple as-converted basis, before options and awards. That is a scenario denominator rather than a count of shares legally issued, currently tradable or necessarily issuable immediately under ownership restrictions. Form 10-Q, Note 9: common stock and pre-funded warrants

At September 30 the reserve table reported 11,273,533 options outstanding and 4,946,984 restricted and performance stock units, distinct from 3,819,646 shares available for future awards and 4,799,623 available under the employee stock purchase plan. Including all currently outstanding options and units in the simple warrant-adjusted scenario gives 127,820,164 potential common equivalents before future awards, a Merlintrader calculation that does not apply treasury-stock accounting, vesting probabilities, net settlement or exercise economics. Unused plan authorizations are not existing grants. The board’s flexibility to issue in the future, including against 300 million authorized common shares at the quarter-end, is a separate issue from the securities already issued. Form 10-Q, reserve table and stock-based compensation

The reported 105,176,101 weighted-average basic and diluted shares in the September-quarter loss per share should not be reconciled by substituting the quarter-end legal share count. The period average includes pre-funded warrants under the issuer’s loss-per-share policy because their exercise price is nominal. Other potential shares were excluded from diluted loss per share where they would be anti-dilutive. This can make a larger reported denominator coexist with genuine exposure to future issuance. A period average used to compute a loss per share is also different from a period-end count used to measure ownership. Form 10-Q, Note 12: net loss per share and share denominator

The filing also describes the Leerink at-the-market (ATM) arrangement with an aggregate authorization of up to $100 million. That is sale authority, not an amount of undrawn cash or a second equity financing that already occurred. The company reported no sales under the ATM arrangement in the three or six months ended September 30, 2026. The six-month financing statement separately identifies the August public offering, the Hercules draw and option-exercise proceeds. The disclosed debt is shown as a term facility, not as a convertible note in the dilution table. Keeping these categories separate avoids counting contingent rights twice or treating unsold securities as balance-sheet resources. Form 10-Q, equity disclosures and financing cash flows

12 Ownership filings, insider sales and market liquidity

Autumn beneficial-ownership filings show why the date of the position matters more than the date a headline appears. RTW Investments reported 8,491,525 beneficially owned shares, 9.0%, in a Schedule 13G/A filed November 16. State Street’s November 10 Schedule 13G reported 4,174,260 shares, 4.4%, and the November 9 amendment from the Goldman Sachs reporting entities reported 3,115,243.18 beneficially owned shares, 3.3%. All three disclosures give September 30, 2026 as the effective date. These are disclosures of voting or investment power under the filers’ stated rules, not purchases executed on the filing dates. A position reported by a fund and by the fund’s controlling person can refer to the same underlying shares. RTW Schedule 13G/A ยท November 10 Schedule 13G ยท Goldman Sachs Schedule 13G/A

On November 6 the company amended its September quarterly report to add Rule 10b5-1 arrangements to Part II, Item 5. The amendment did not restate the financial statements. A trading plan provides for potential transactions under stated conditions; the maximum share count in a plan is not an executed sale. Separately, four Forms 4 filed November 18 reported November 16 transactions coded S. The four entries total 82,081 shares. The footnotes identify nondiscretionary sales to cover tax withholding on vested restricted stock units under irrevocable award provisions. The later Forms 144 are notices of proposed transactions and do not, by themselves, show that those proposed transactions closed. Form 10-Q/A, explanatory note and Item 5 ยท Form 4, 129852 ยท Form 4, 129853 ยท Form 4, 129854 ยท Form 4, 129855 ยท November 20 Form 144

A Form 4 code helps prevent an ownership disclosure from becoming the wrong economic story. P identifies a purchase, S a sale, M an exercise or conversion under the applicable exemption, A an award or grant and F withholding or delivery of securities for an exercise price or tax liability. A grant can enlarge an individual’s long-term exposure without requiring a cash purchase. An exercise and related disposition might appear next to each other and still describe separate transactions. That is different again from a Schedule 13G, which is a beneficial-ownership snapshot rather than an insider transaction report. SEC Form 4 transaction-code instructions

The September 10-Q cover identifies REPL as listed on the Nasdaq Global Select Market. Trading liquidity should be read together with, but not confused with, corporate liquidity or beneficial-ownership filings. Nasdaq reported 24,609,876 shares short at the October 30 settlement, approximately 26.0% of the October 23 legal common count (Merlintrader calculation, not a fraction of tradable float). Average daily share volume was 2,959,938, or about 8.31 days to cover. Nasdaq settlement series. FINRA’s published timetable lists November 24 as the publication date for short interest at the November 13 settlement. Open short positions are a stock of outstanding positions at a date; daily short-sale volume measures trades and is not a substitute. A days-to-cover calculation uses an average daily volume and is not a deadline for short sellers. Concentrated positioning can magnify moves around new information without changing what the company must demonstrate commercially or clinically. Listing on the Form 10-Q cover ยท FINRA reporting calendar

13 Litigation and what would change the investment case

The October filing disclosed securities litigation in the U.S. District Court for the District of Massachusetts. In case 1:25-cv-12085, the defendants moved on August 17, 2026 to dismiss a second amended complaint; the filing said briefing was scheduled to finish in December. It also described a related case, 1:26-cv-13612, and a motion to consolidate it with the earlier action. The company reported that three shareholder derivative actions had been consolidated and stayed pending developments in the first class action. The defendants deny wrongdoing. The October filing’s procedural dates are not findings on liability and the briefing window is not a ruling date. Form 10-Q, Part II, Item 1: Legal Proceedings

Regulatory and legal risk can be related without being interchangeable. A complaint over alleged securities disclosures addresses what was said and when; a subsequent FDA authorization addresses the risk-benefit and legal basis for marketing a drug in a defined setting. Neither proceeding should be treated as a verdict in the other. The 10-Q discusses litigation contingencies and the judgment involved in recording a liability. In assessing financial exposure, a future court ruling or a disclosed financial obligation would matter more than recycling the original allegations. Form 10-Q, Note 15 and Legal Proceedings ยท FDA accelerated approval letter

The near-term assessment comes down to three statements that must be able to coexist: early clinical adoption can be real, cash needs can still be substantial, and confirmatory benefit can still be uncertain. The first thing that would change the financial reading is a quarterly bridge from use to net sales to cash. The first thing that would change the clinical reading is evidence that addresses the randomized comparison. A disclosure can be material without solving both at once. Investors watching only approvals could miss an unfavorable cost trend; investors watching only sales could miss the trial risk underlying continued approval.

For that reason, the clearest next report would do more than announce a commercial number. It would distinguish new centers from repeat utilization, relate the sales line to receivables and cash, and explain funding priorities across the launch and the pipeline. An outcome that makes one of those bridges stronger without weakening the others would improve the case. If the gaps persist, the company could remain dependent on access to outside financing for much longer than the first deliveries would suggest.

Merlintrader Health Score ยท $REPL

3.0out of 5
Balance sheet and runway ยท 30%3.5

September 30 cash and equivalents of $307.833 million versus $100 million of face debt; material first-half operating cash use and lender liquidity tests. Form 10-Q

Catalyst ยท 30%3.0

The first post-launch reporting period is underway; no results date has been announced. Confirmatory survival remains a longer-dated requirement. IR ยท FDA

Dilution ยท 20%2.0

August equity issuance and 16.8 million quarter-end pre-funded warrants limit the benefit of using the undiluted share count. Form 10-Q

Liquidity ยท 10%3.0

Nasdaq Global Select Market listing; at the October 30 settlement, Nasdaq reported 24.61 million shares short against 2.96 million in average daily volume, about 8.31 days to cover. Form 10-Q ยท Nasdaq series

Execution ยท 10%3.5

October launch and first patient deliveries were announced; repeat uptake and cash conversion are not yet visible in the September financials. October 28 update

Assessed November 21, 2026. Weighted calculation: 3.5 ร— 30% + 3.0 ร— 30% + 2.0 ร— 20% + 3.0 ร— 10% + 3.5 ร— 10% = 3.0 out of 5. The score assesses financial and operational resilience; it is not an investment recommendation.

Red flags

  • Early formulary access has yet to translate into reported product sales or collections.
  • IGNYTE-3 must address clinical benefit; survival is not answered by the original single-arm response data.
  • Hercules cash conditions can constrain deployable funds even before contractual maturity.
  • Quarter-end pre-funded warrants create substantial potential share exposure beyond the legal count.
  • The October filing reports two related securities cases and consolidated derivative actions.

REPL Stock FAQ: Replimune Group Questions Answered

When is the next REPL stock catalyst?

As of November 21, 2026, Replimune had not announced a date for its next financial report. The fiscal quarter ending December 31 is the first period with U.S. commercial availability, making reported net sales and working capital the next financial tests. Company announcements

Is Replimune’s TUDRIQEV FDA approved?

Yes. On August 6, 2026 the FDA granted accelerated approval with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking antibody-based regimen. Continued approval may depend on confirmation of clinical benefit in IGNYTE-3. FDA approval notice ยท Postmarketing requirement

How much cash does Replimune have, and how long will it last?

Replimune reported $307.833 million of cash and equivalents as of September 30, 2026. Management expected resources to cover more than twelve months from issuance of the interim statements, including commercialization needs. That outlook does not extend by implication to the final confirmatory report. Form 10-Q

Is REPL stock at risk of dilution?

Yes. The October 28 Form 10-Q reported 16,794,493 shares underlying pre-funded warrants as of September 30, 2026 in addition to basic common shares, and separate outstanding options and restricted or performance units. Issuing previously unissued shares can reduce existing holders’ percentage interest. Form 10-Q, reserve table

When did Replimune last report earnings?

Replimune reported fiscal second-quarter 2027 results for the period ended September 30, 2026 on October 28. It reported no product revenue for the period and a net loss of $57.121 million. The fiscal year ends March 31. Results release ยท Form 10-Q

What does Replimune Group do?

Replimune commercializes a cancer immunotherapy and develops earlier oncology candidates. On October 1, 2026 it announced U.S. availability of TUDRIQEV for its labeled melanoma use; RP2 remained investigational. Launch release ยท Pipeline update

Has Replimune resolved its earlier going-concern warning?

The September 2026 10-Q states that the August financing alleviated the conditions giving rise to substantial doubt at March 31, 2026. That is the company’s conclusion for the accounting assessment, not a statement that additional capital will never be needed. Form 10-Q, Note 1

What are Replimune’s Hercules loan covenant tests?

As of the October 28, 2026 Form 10-Q, the Hercules performance covenant describes net product revenue and alternative cash tests at the applicable principal threshold. The 50% cash route also requires the specified contractual capitalization threshold; another route requires cash of at least 85% of outstanding term loans. A separate continuous cash floor remains under the fourth amendment. Form 10-Q, Note 8 ยท Fourth amendment

Primary sources and clinical literature

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice or medical advice, nor is it an offer, solicitation or investment recommendation. Verify data against the primary sources before acting.

Oncology biotechnology companies face clinical, regulatory, reimbursement, commercialization and financing risks, including dilution and loss of capital. Readers remain responsible for their decisions and should consult a licensed financial adviser where appropriate. Accelerated approval may be contingent on confirmation of clinical benefit. Early adoption, trial outcomes, cash needs and access to capital can differ materially from expectations.

Some links on this page are affiliate or referral links, including Finviz, which may generate a commission at no cost to the reader.

Merlintrader may hold positions in securities mentioned. See the disclaimer and terms of use and privacy.